---
title: "Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287724562.md"
description: "Annovis Bio, Inc. (ANVS) has regained compliance with NYSE listing standards within 12 months, ahead of the 18-month cure period. The company implemented corrective measures after being notified of non-compliance due to low market capitalization and stockholders' equity. Annovis will continue trading on the NYSE and focus on advancing its clinical programs, including the pivotal Phase 3 study for its lead drug candidate, Buntanetap. ANVS closed at $2.06, down 7.62%."
datetime: "2026-05-27T06:15:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287724562.md)
  - [en](https://longbridge.com/en/news/287724562.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287724562.md)
---

# Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period

(RTTNews) - Annovis Bio, Inc. (ANVS), a clinical-stage biotechnology company, on Tuesday announced that it regained compliance with the New York Stock Exchange (NYSE) continued listing standards. Notably, the firm has regained full compliance within about 12 months, ahead of the 18-month cure period.

Annovis' lead drug candidate in development is Buntanetap, an investigational once-daily oral therapy designed to treat neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD).

On March 26, 2025, the NYSE notified Annovis of its non-compliance with the NYSE Listed Company Manual because its averageglobal marketcapitalisation was below $50 million over a consecutive 30-trading-day period, and its stockholders' equity was also below $50 million.

Following that, on June 19, 2025, the NYSE accepted Annovis' plan to regain compliance and granted an 18-month cure period from the date of the original notice.

As part of its plan to regain compliance, Annovis implemented a series of corrective measures to restore its market capitalisation and stockholders' equity to levels above the required thresholds, and it provided the NYSE with quarterly progress updates, the firm noted.

Having regained full compliance, Annovis will continue to be listed and traded on the NYSE under the symbol "ANVS".

"With this matter behind us, our attention remains firmly on advancing our clinical programs toward key milestones, with topline data readout from the pivotal Phase 3 AD study and the regulatory submissions on the horizon," said Alexander Morin, Director, Strategic Communications.

ANVS has traded between $1.54 and $5.50 over the last year. ANVS closed Tuesday's trading at $2.06, down 7.62%.

ANVS is down 0.49% at $2.05 in the after-hours market.

For More Such Biotech Stock News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [ANVS.US](https://longbridge.com/en/quote/ANVS.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Annovis Unchanged on Hookup with NeuroRPM](https://longbridge.com/en/news/279801439.md)